First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status. Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Gettinger, Scott N
  • Shepherd, Frances A
  • Antonia, Scott Joseph
  • Brahmer, Julie R
  • Chow, Laura Quan Man
  • Juergens, Rosalyn
  • Borghaei, Hossein
  • Shen, Yun
  • Harbison, Christopher
  • Alaparthy, Suresh
  • Chen, Allen C
  • Rizvi, Naiyer A

publication date

  • May 20, 2014